

CITATION REPORT

List of articles citing

Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma

DOI: 10.1186/s12885-016-2633-2
BMC Cancer, 2016, 16, 598.

Source: <https://exaly.com/paper-pdf/63653858/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
4	Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021 , 21, 923-941	2.2	
3	Systematic Literature Review of Economic Evaluations, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell Lymphoma. <i>PharmacoEconomics - Open</i> , 2021 , 5, 175-186	2.1	1
2	First-Line Treatment of Mantle-Cell Lymphoma: Analysis of Effectiveness and Cost-Effectiveness. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2018 , 11, 150-159	0.3	1
1	Analysis Results of the Regional Registry of Patients with Diffuse Large B-cell Lymphoma: Risk Factors and Chemo-Immunotherapy Issues. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2019 , 12, 154-164	0.3	3